SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
________________
Date of Report (Date of earliest event reported):
November 17, 2000
Alpharma Inc.
(Exact name of registrant as specified in its charter)
Delaware 1-8593 22-2095212
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification
incorporation) No.)
One Executive Drive, Fort Lee, New Jersey 07024
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code
(201) 947-7774
Not Applicable
________________________________________________
(Former name or former address, if changed since
last report)
Item 9. Regulation FD Disclosures
Consistent with the estimates for the fiscal year ending
December 31, 2000, as contained in the Company's press release of
October 30, 2000 (incorporated by reference under Item 9 of the
Company's Form 8-K dated October 30, 2000), the Company has the
following approximate targets for revenues and operating income
for the fiscal year ended December 31, 2000, when segmenting its
business as indicated below:
Human Pharmaceuticals
Revenue $610 million
Operating Income $90 million
Animal Pharmaceuticals
Revenue $315 million
Operating Income $60 million (1)
(1) Excludes one time charge for Roche MFA acquisition.
The statements in this Item 9 are forward-looking statements
within the meaning of the Private Securities Litigation Reform
Act of 1995. Forward-looking statements involve risks and
uncertainties which could cause actual results to differ
materially from those stated in the forward-looking statements.
Risks and uncertainties include, but are not limited to, those
risks described in the "Risk Factors" section of the Company's 10-
K/A report for the year ended December 31, 1999 and in the
"Management's Discussion and Analysis" section of its 10-Q report
for the quarter ended September 30, 2000 and those in its other
SEC Filings.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
Alpharma Inc.
By: /s/ Ingrid Wiik
Ingrid Wiik
President and Chief Executive
Officer
Date: November 17, 2000
